Many non-small cell lung cancers (NSCLC) fail to respond to standard therapies, or they return despite these treatments. Researchers are therefore seeking more effective treatments. The purpose of this study is to assess the safety and effectiveness of an investigational drug called MPDL3280A in patients with locally advanced or metastatic NSCLC.
MPDL3280A is designed to improve the immune system’s ability to recognize and destroy cancer cells by blocking PD-L1, a protein made by some cancers. Patients in this study must have NSCLC tumors that express PD-L1. MPDL3280A is given intravenously (by vein).